Safety Considerations with Fibrate Therapy

American Journal of Cardiology

Volumn 99, Issue 6 SUPPL. 1, 2007, Pages

  Davidson, Michael H ^a   Armani, Annemarie ^b   McKenney, James M ^c   Jacobson, Terry A ^d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Imprint Science   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; CREATININE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; MEVINOLIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PRAVASTATIN; REPAGLINIDE; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN;

ABDOMINAL PAIN; ARTICLE; BASAL CELL CARCINOMA; CHOLECYSTITIS; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM CANCER; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LUNG EMBOLISM; MONOTHERAPY; MORTALITY; MYOPATHY; PANCREATITIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STOMACH PAIN; TRIACYLGLYCEROL BLOOD LEVEL; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTILIPEMIC AGENTS; CHOLELITHIASIS; CLINICAL TRIALS; CLOFIBRIC ACID; CREATININE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RHABDOMYOLYSIS;

EID: 33947110940     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.11.016     Document Type: Article

References (133)

1. Brown W.V. Potential use of fenofibrate and other fibric acid derivatives in the clinic. Am J Med 83 (1987) 85-89
2. Blane G.F. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 83 (1987) 26-36
3. Devuyst O., Goffin E., Pirson Y., and van Ypersele de Strihou C. Creatinine rise after fibrate therapy in renal graft recipients. Lancet 341 (1993) 840
4. Hottelart C., El Esper N., Rose F., Achard J.M., and Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92 (2002) 536-541
5. Ritter J.L., and Nabulsi S. Fenofibrate-induced elevation in serum creatinine. Pharmacotherapy 21 (2001) 1145-1149
6. Broeders N., Knoop C., Antoine M., Tielemans C., and Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?. Nephrol Dial Transplant 15 (2000) 1993-1999
7. Lipscombe J., Lewis G.F., Cattran D., and Bargman J.M. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 55 (2001) 39-44
8. Rossner S., and Oro L. Fenofibrate therapy of hyperlipoproteinaemia. a dose-response study and a comparison with clofibrate. Atherosclerosis 38 (1981) 273-282
9. Rouffy J., Chanu B., Bakir R., Djian F., and Goy-Loeper J. Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. Atherosclerosis 54 (1985) 273-281
10. Boissonnat P., Salen P., Guidollet J., Ferrera R., Dureau G., Ninet J., Renaud S., and de Lorgeril M. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 58 (1994) 245-247
11. Williams A.J., Baker F., and Walls J. The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia. Br J Clin Pharmacol 18 (1984) 361-367
12. Lageder H. Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia. Wien Klin Wochenschr 92 (1980) 95-101
13. Dick T.B., Marples J., Ledermann H.M., and Whittington J. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia. Curr Med Res Opin 7 (1981) 489-502
14. Bruce R., Daniels A., and Cundy T. Renal function changes in diabetic nephropathy induced by bezafibrate. Nephron 73 (1996) 490
15. Levin A., Duncan L., Djurdjev O., Shapiro R.J., Frohlich J., Belanger A., Dumas R., and Ross S. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clin Nephrol 53 (2000) 140-146
16. Deighan C.J., Caslake M.J., McConnell M., Boulton-Jones J.M., and Packard C.J. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J Am Soc Nephrol 12 (2001) 341-348
17. Dalton R.N., Crimet D., and Ansquer J.C. The Effect of Fenofibrate on Glomerular Filtration Rate (GFR) and Other Renal Function Tests: A Double-Blind Placebo-Controlled Cross-Over Study in Healthy Subjects (2005), American Society of Nephrology, Philadelphia
18. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
19. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., and Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45 (2005) 485-493
20. Davidson M.H. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 5 (2006) 145-156
21. Tsimihodimos V., Miltiadous G., Bairaktari E., and Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol 57 (2002) 407-408
22. Tsimihodimos V., Kakafika A., and Elisaf M. Fibrate treatment can increase serum creatinine levels. [letter]. Nephrol Dial Transplant 16 (2001) 1301
23. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., and Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11 (1997) 779-791
24. Hottelart C., el Esper N., Achard J.M., Pruna A., and Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 20 (1999) 41-44
25. Brown W.V., Dujovne C.A., Farquhar J.W., Feldman E.B., Grundy S.M., Knopp R.H., Lasser N.L., Mellies M.J., Palmer R.H., Samuel P., et al. Effects of fenofibrate on plasma lipids. double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 6 (1986) 670-678
26. de Lorgeril M., Salen P., Paillard F., Lacan P., and Richard G. Lipid-lowering drugs and homocysteine. Lancet 353 (1999) 209-210
27. Dierkes J., Westphal S., and Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 354 (1999) 219-220
28. Westphal S., Dierkes J., and Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358 (2001) 39-40
29. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
30. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J., and Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
31. Angeles C., Lane B.P., Miller F., and Nord E.P. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. Am J Kidney Dis 44 (2004) 543-550
32. Lipscombe J., and Bargman J.M. Fibrate-induced increase in blood urea and creatinine. [letter]. Nephrol Dial Transplant 16 (2001) 1515
33. Tonelli M., Collins D., Robins S., Bloomfield H., Curhan G.C., and Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. for the. Kidney Int 66 (2004) 1123-1130
34. Tricor [fenofibrate]. Mosby's Drug Consult. 16th ed. (2006), Elsevier, Philadelphia [database online]
35. Kasiske B., Cosio F.G., Beto J., Bolton K., Chavers B.M., Grimm Jr. R., Levin A., Masri B., Parekh R., Wanner C., Wheeler D.C., and Wilson P.W. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4 suppl (2004) 13-53
36. Evans J.R., Forland S.C., and Cutler R.E. The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol 27 (1987) 994-1000
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
38. Angelin B., Einarsson K., and Leijd B. Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid. Eur J Clin Invest 11 (1981) 185-189
39. Leiss O., von Bergmann K., Gnasso A., and Augustin J. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects. Metabolism 34 (1985) 74-82
40. Hall M.J., Nelson L.M., Russell R.I., and Howard A.N. Gemfibrozil-the effect of biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate. Atherosclerosis 39 (1981) 511-516
41. Leiss O., Meyer-Krahmer K., and von Bergmann K. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. influence of bezafibrate and fenofibrate. J Lipid Res 27 (1986) 213-223
42. von Bergmann K., and Leiss O. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia. Eur J Clin Invest 14 (1984) 150-154
43. Caroli-Bosc F.X., Le Gall P., Pugliese P., Delabre B., Caroli-Bosc C., Demarquay J.F., Delmont J.P., Rampal P., and Montet J.C. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig Dis Sci 46 (2001) 540-544
44. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression on coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
45. Frick M.H., Syvänne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., Kesaniemi Y.A., Pasternack A., Taskinen M.R., and Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 96 (1997) 2137-2143
46. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. report from the Committee of Principal Investigators. Br Heart J 40 (1978) 1069-1118
47. Carlson L.A., and Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 (1988) 405-418
48. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
49. Sudhop T., Lutjohann D., Kodal A., Igel M., Tribble D.L., Shah S., Perevozskaya I., and von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106 (2002) 1943-1948
50. Zetia [ezitimibe]. Mosby's Drug Consult. 16th ed. (2006), Elsevier, Philadelphia, Pennsylvania [database online]
51. McKenney J.M., Farnier M., Lo K.W., Bays H.E., Perevozkaya I., Carlson G., Davies M.J., Mitchel Y.B., and Gumbiner B. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 47 (2006) 1584-1587
52. Paragh G., Balogh Z., and Romics L. Antilipemic therapy and rhabdomyolysis. Orv Hetil 144 (2003) 515-520
53. Gaist D., Rodríguez L.A., Huerta C., Hallas J., and Sindrup S.H. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12 (2001) 565-569
54. Graham D.J., Staffa J.A., Shatin D., Andrade S.E., Schech S.D., La Grenade L., Gurwitz J.H., Chan K.A., Goodman M.J., and Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 (2004) 2585-2590
55. Chang J.T., Staffa J.A., Parks M., and Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 13 (2004) 417-426
56. Layne R.D., Sehbai A.S., and Stark L.J. Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann Pharmacother 38 (2004) 232-234
57. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., and Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 165 (2005) 1154-1160
58. Kanterewicz E., Sanmarti R., Riba J., Trias I., Autonell J., and Brugues J. Bezafibrate induced rhabdomyolysis. Ann Rheum Dis 51 (1992) 536-538
59. Clouatre Y., Leblanc M., Ouimet D., and Pichette V. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol Dial Transplant 14 (1999) 1047-1048
60. Pierce L.R., Wysowski D.K., and Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264 (1990) 71-75
61. Kijima Y., Sasaoka T., Kanayama M., and Kubota S. Untoward effects of clofibrate in hemodialyzed patients. N Engl J Med 296 (1977) 515
62. Langford N.J., and Kendall M.J. Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?. J Clin Pharm Ther 26 (2001) 391-395
63. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. Risk of adverse events with fibrates. Am J Cardiol 94 (2004) 935-938
64. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540
65. Grundy S.M., Vega G.L., Yuan Z., Battisti W.P., Brady W.E., and Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia. (the SAFARI trial). Am J Cardiol 95 (2005) 462-468
66. Neil A., Wheeler F., Cull C., Manley S., Keenan J., and Holman R. Combination statin and fibrate therapy in type 2 diabetes: results from the Lipids in Diabetes Study. [abstract]. Diabetes 52 suppl (2003) A74
67. Tobert J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62 suppl (1988) 28J-34J
68. Tal A., Rajeshawari M., and Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 90 (1997) 546-547
69. Rosenson R.S. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408-416
70. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
71. Oldemeyer J.B., Lund R.J., Koch M., Meares A.J., and Dunlay R. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. Cardiology 94 (2000) 127-128
72. Raimondeau J., Le Marec H., Chevallier J.C., and Bouhour J.B. Biological myolysis during combined fenofibrate-pravastatin therapy. Presse Med 21 (1992) 663-664
73. Kamaliah M.D., and Sanjay L.D. Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives. Singapore Med J 42 (2001) 368-372
74. Jacobson T.A., and Zimmerman F.H. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich) 8 (2006) 35-41
75. Backman J.T., Kyrklund C., Neuvonen M., and Neuvonen P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72 (2002) 685-691
76. Backman J.T., Kyrklund C., Kivisto K.T., Wang J.S., and Neuvonen P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68 (2000) 122-129
77. Kyrklund C., Backman J.T., Kivisto K.T., Neuvonen M., Laitila J., and Neuvonen P.J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69 (2001) 340-345
78. Kyrklund C., Backman J.T., Neuvonen M., and Neuvonen P.J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73 (2003) 538-544
79. Lipitor [atorvastatin]. Mosby's Drug Consult. 16th ed. (2006), Elsevier, Philadelphia, Pennsylvania [database online]
80. Crestor [rosuvastatin]. Mosby's Drug Consult. 16th ed. (2006), Elsevier, Philadelphia, Pennsylvania [database online]
81. Spence J.D., Munoz C.E., Hendricks L., Latchinian L., and Khouri H.E. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 76 suppl (1995) 80A-83A
82. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., and Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
83. Prueksaritanont T., Zhao J.J., Ma B., Roadcap B.A., Tang C., Qiu Y., Liu L., Lin J.H., Pearson P.G., and Baillie T.A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301 (2002) 1042-1051
84. Wang J.S., Wen X., Backman J.T., and Neuvonen P.J. Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes. J Pharmacol Exp Ther 302 (2002) 43-49
85. Owczarek J., Jasinska M., and Orszulak-Michalak D. Drug-induced myopathies. an overview of the possible mechanisms. Pharmacol Rep 57 (2005) 23-34
86. Shek A., and Ferrill M.J. Statin-fibrate combination therapy. Ann Pharmacother 35 (2001) 908-917
87. Pan W.J., Gustavson L.E., Achari R., Rieser M.J., Ye X., Gutterman C., and Wallin B.A. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 40 (2000) 316-323
88. Martin P.D., Dane A.L., Schneck D.W., and Warwick M.J. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 25 (2003) 459-471
89. Bergman A.J., Murphy G., Burke J., Zhao J.J., Valesky R., Liu L., Lasseter K.C., He W., Prueksaritanont T., Qiu Y., et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 44 (2004) 1054-1062
90. Penn R., Williams III R.X., Guha-Ray D.K., Sawyers W.G., Braun S.L., and Rains K.T. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Clin Ther 28 (2006) 45-54
91. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
92. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., and Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 33 (2002) 2337-2341
93. Heady J.A., Morris J.N., and Oliver M.F. WHO clofibrate/cholesterol trial: clarifications. Lancet 340 (1992) 1405-1406
94. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 2 (1980) 379-385
95. Huttunen J.K., Heinonen O.P., Manninen V., Koskinen P., Hakulinen T., Teppo L., Mänttäri M., and Frick M.H. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med 235 (1994) 31-39
96. Frick M.H., Heinonen O.P., Huttunen J.K., Koskinen P., Mänttäri M., and Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease: an ancillary study in the Helsinki Heart Study frame population. Ann Med 25 (1993) 41-45
97. Atromid-S [clofibrate]. Mosby's Drug Consult. 16th ed. (2006), Elsevier, Philadelphia, Pennsylvania [database online]
98. Tenkanen L., Mänttäri M., Kovanen P.T., Virkkunen H., and Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 166 (2006) 743-748
99. Den Heijer M., Lewington S., and Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 3 (2005) 292-299
100. Mayer Jr. O., Šimon J., Holubec L., Pikner R., Vobrubová I., and Trefil L. Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients. Eur J Cardiovasc Prev Rehabil 11 (2004) 244-249
101. Landray M.J., Townend J.N., Martin S., Martin U., and Wheeler D.C. Lipid-lowering drugs and homocysteine. Lancet 353 (1999) 1974-1975
102. Bissonnette R., Treacy E., Rozen R., Boucher B., Cohn J.S., and Genest Jr. J. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis 155 (2001) 455-462
103. Okopien B., Cwalina L., Lebek M., Kowalski J., Zielinski M., Wisniewska-Wanat M., Kalina Z., and Herman Z.S. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int J Clin Pharmacol Ther 39 (2001) 551-557
104. Branchi A., Rovellini A., Sommariva D., Gugliandolo A.G., and Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 70 (1993) 241-243
105. Zhao S.P., Li J., Xu Z., Wu J., Li Q., and Ye H. Fenofibrate inhibits thrombogenic and fibrinolytic factors expression in adipose tissue of atherosclerotic rabbits. Clin Chim Acta 349 (2004) 81-86
106. Fujii S., and Sobel B.E. Direct effects of gemfibrozil on the fibrinolytic system. diminution of synthesis of plasminogen activator inhibitor type 1. Circulation 85 (1992) 1888-1893
107. Fujii S., Sawa H., and Sobel B.E. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb Haemost 70 (1993) 642-647
108. O'Brien J.R., Etherington M.D., Shuttleworth R.D., Adams C.M., Middleton J.E., and Goodland F.C. A pilot study of the effect of Gemfibrozil on some haematological parameters. Thromb Res 26 (1982) 275-279
109. Stringer M.D., Steadman C.A., and Kakkar V.V. Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions. Curr Med Res Opin 12 (1990) 207-214
110. Wilkes H.C., Meade T.W., Barzegar S., Foley A.J., Hughes L.O., Bauer K.A., Rosenberg R.D., and Miller G.J. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost 67 (1992) 503-506
111. Avellone G., Di Garbo V., Panno A.V., Cordova R., Lepore R., and Strano A. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int Angiol 7 (1988) 270-277
112. Agrati A., Ambrosi G., and Ferraro G. Gemfibrozil efficacy vs pantetine in dyslipoproteinemic patients: a controlled study. Curr Ther Res 45 (1989) 650-663
113. Vague P., Juhan-Vague I., Aillaud M.F., Badier C., Viard R., Alessi M.C., and Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35 (1986) 250-253
114. Juhan-Vague I., Vague P., Alessi M.C., Badier C., Valadier J., Aillaud M.F., and Atlan C. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab 13 (1987) 331-336
115. Mehta J., Mehta P., Lawson D., and Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 9 (1987) 263-268
116. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288 (2002) 2015-2022
117. Syvänne M., Whittall R.A., Turpeinen U., Nieminen M.S., Frick M.H., Kesäniemi Y.A., Pasternack A., Humphries S.E., and Taskinen M.R. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis 172 (2004) 267-272
118. Jonkers I.J., de Man F.H., Onkenhout W., van der Laarse A., and Smelt A.H. Implication of fibrate therapy for homocysteine. Lancet 354 (1999) 1208-1209
119. Giral P., Bruckert E., Jacob N., Chapman M.J., Foglietti M.J., and Turpin G. Homocysteine and lipid lowering agents. a comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 154 (2001) 421-427
120. Genest J., Frohlich J., and Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 93 (2004) 848-853
121. Keech T. Update on fibrates: prevention of macrovascular and microvascular events in diabetes mellitus patients-new insights from the FIELD Study. Presented at the American Heart Association Scientific Sessions; November 12, 2006; Chicago, Illinois.
122. Goffin E., Jamar F., Desager J.P., and Devuyst O. Implication of fibrate therapy for homocysteine. Lancet 354 (1999) 1209
123. Luc G., Jacob N., Bouly M., Fruchart J.C., Staels B., and Giral P. Fenofibrate increases homocystinemia through a PPARα-mediated mechanism. J Cardiovasc Pharmacol 43 (2004) 452-453
124. Eikelboom J.W., Lonn E., Genest Jr. J., Hankey G., and Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131 (1999) 363-375
125. Melenovsky V., Stulc T., Kozich V., Grauova B., Krijt J., Wichterle D., Haas T., Malik J., Hradec J., and Ceska R. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. Am Heart J 146 (2003) 110 [clinical investigation]
126. Mayer Jr. O., Šimon J., Holubec L., Pikner R., and Šubrt I. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur J Clin Pharmacol 59 (2003) 367-371
127. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., McQueen M.J., Probstfield J., Fodor G., Held C., and Genest Jr. J. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006) 1567-1577
128. Bønaa K.H., Njølstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., Wang H., Nordrehaug J.E., Arnesen E., and Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
129. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., and Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
130. Ascah K.J., Rock G.A., and Wells P.S. Interaction between fenofibrate and warfarin. Ann Pharmacother 32 (1998) 765-768
131. Schrogie J.J., and Solomon H.M. The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate, and norethandrolone. Clin Pharmacol Ther 8 (1967) 70-77
132. Solomon H.M., Schrogie J.J., and Williams D. The displacement of phenylbutazone-14C and warfarin-14C from human albumin by various drugs and fatty acids. Biochem Pharmacol 17 (1968) 143-151
133. Solomon H.M., and Schrogie J.J. The effect of various drugs on the binding of warfarin-14C to human albumin. Biochem Pharmacol 16 (1967) 1219-1226